Guardant to develop CDx and TMB liquid biopsy tests for AstraZeneca’s targeted cancer therapies
| Fierce Biotech

AstraZeneca has tapped Guardant Health to develop blood-based companion diagnostics for its cancer treatments Tagrisso and Imfinzi. Under the multiyear agreement, Guardant will pursue an FDA approval for a Guardant360 CDx liquid biopsy test to help identify non-small cell lung cancer patients for treatment with Tagrisso, an EGFR inhibitor.

Meet Hal: A robot that helps train health workers for a crisis
| Star Tribune

Five-year old Hal was showing dangerous signs of respiratory distress. His lips were turning blue, his eyelids were drooping and the bedside monitor showed oxygen levels in his blood dropping fast.

FSD Pharma Inc. Growing the Future Through Innovation
| CannaInvestor

FSD Pharma is transforming the former Kraft plant in Cobourg, Ontario, into the largest hydroponic indoor cannabis production and processing facility in the world.